3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Lymphoma
21
Neutropenia
13
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, Non-Hodgkin
11
Neoplasms
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Carcinoma, Non-Small-Cell Lung
8
Multiple Myeloma
7
Leukemia
7
Burkitt Lymphoma
7
Ovarian Neoplasms
6
Lymphoma, Follicular
6
Lung Neoplasms
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Urinary Bladder Neoplasms
4
Testicular Neoplasms
4
Sarcoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, B-Cell, Marginal Zone
4
Hodgkin Disease
4
Central Nervous System Neoplasms
4
Testicular Germ Cell Tumor
3
Teratoma
3
Rhabdomyosarcoma
3
Chemotherapy-induced Neutropenia
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Embryonal
3
Adenocarcinoma, Bronchiolo-Alveolar
3
Interventions
Trastuzumab
11
pyrotinib
8
pertuzumab
5
Docetaxel
5
trastuzumab deruxtecan
2
Paclitaxel
2
Carboplatin
2
Capecitabine
2
tucatinib
1
pegfilgrastim
1
neratinib
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
envafolimab
1
dalpiciclib
1
atezolizumab
1
Neoadjuvant Therapy
1
Metformin
1
Leuprolide
1
Goserelin
1
Fulvestrant
1
Drug Therapy
1
Anastrozole
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
HER2-positive Breast Cancer
×
pegfilgrastim
×
Clear all
NCT03571633
2025-11-26
BREASTIMMU02
Centre Leon Berard
Phase 2
Active not recruiting
90 enrolled